Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

BACKGROUND: This phase 1 study evaluated the maximum tolerated dose (MTD), safety, and efficacy of bosutinib (competitive Src/Abl tyrosine kinase inhibitor) plus capecitabine. METHODS: Patients with locally advanced/metastatic breast, pancreatic, or colorectal cancers; cholangiocarcinoma; or gliobla...

Descripción completa

Detalles Bibliográficos
Autores principales: Isakoff, S J, Wang, D, Campone, M, Calles, A, Leip, E, Turnbull, K, Bardy-Bouxin, N, Duvillié, L, Calvo, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260032/
https://www.ncbi.nlm.nih.gov/pubmed/25290090
http://dx.doi.org/10.1038/bjc.2014.508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4260032/
https://www.ncbi.nlm.nih.gov/pubmed/25290090
http://dx.doi.org/10.1038/bjc.2014.508

Ejemplares similares